Maravai LifeSciences Holdings Inc. (MRVI): What is the Risk Factor?

Maravai LifeSciences Holdings Inc. (NASDAQ:MRVI) saw a downside of -16.40% on Friday at $41.03 after subtracting -$8.05. The 5-day average trading volume is 1,343,917 shares of the company’s common stock. It has gained $49.95 in the past week. An average of 2,730,484 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 1,677,340.

MRVI’s 1-month performance is -17.07% or -$16.33 on its low of $40.56 reached on 10/01/21. The company’s shares have touched a 52-week low of $23.62 and high of $63.55. YTD, MRVI has achieved 74.97% or $13.61. However, the current price is down -35.44%% from the 52-week high price.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Valuation Metrics

Maravai LifeSciences Holdings Inc. (MRVI) has a trailing price-to-earnings (P/E) ratio of 33.74 for the broader industry and 32.21 for the sector, meaning that investors are optimistic about the stock’s future prospects. The company’s PE ratio for the last five years has touched a high of 142.89 and a low of 37.90. MRVI stock has a beta of 0.00. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 33.30 while the price-to-book (PB) in the most recent quarter is 28.37.

Maravai LifeSciences Holdings Inc.’s quick ratio for the period ended June 29 was 3.60, with the current ratio over the same period at 3.90 meaning that MRVI stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 3.00, while the total debt to equity was 3.04The trailing 12-month EBITDA margin is 44.61%. The firm’s gross profit as reported stood at $204.45 million against revenue of $284.1 million.

The effectiveness of a company’s management is also important for investors when it comes to determining the potential profitability of the investment. Return on investment over the past year is 16.10%. In comparison, the average ROE for the broader industry over the past year is -36.91.

Earnings Surprise

For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected MRVI to announce $0.32 per share in earnings in its latest quarter, but it posted $0.44, representing a 37.50% surprise. EBITDA for the quarter stood at more than $162.25 million. MRVI stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 1.27 billion, with total debt at $589.29 million. Shareholders hold equity totaling $257.66 million

Technical Picture

Let’s look briefly at Maravai LifeSciences Holdings Inc. (MRVI) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 30 September was 26.39% to suggest the stock is trending oversold, with historical volatility in this time period at 91.32%.

The stock’s 5-day moving average is $47.09, reflecting a -15.58% or -$7.69 change from its current price. MRVI is currently trading -30.69% above its 20-day SMA, +17.85% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -0.24% and +56.50% respectively.

Stochastic %K and %D was 54.32% and 52.46% and the average true range (ATR) pointed at 3.00. The RSI (14) points at 31.98%, while the 14-day stochastic is at 11.43% with the period’s ATR at 2.94. The stock’s 9-day MACD Oscillator is pointing at -1.38 and -1.08 on the 14-day charts.

Analyst Ratings

Analysts offering their rating for MRVI stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate MRVI as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 1 rates the stock as overweight while 8 have offered a “buy” rating.

What is MRVI’s price target for the next 12 months?

Analysts have a consensus price target ranging from a low of $55.00 and a high of $68.00, with their median price target at $58.50. Looking at these predictions, the average price target given by analysts is for Maravai LifeSciences Holdings Inc. (MRVI) stock is $59.38.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

spot_img

Hot Topics

Related Videos

Related Videos

Related Articles

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

592

100% free. stop anytime no spam